Novo CEO Says Drugmaker Needs to “Rethink” its Obesity Strategy

Novo Nordisk A/S (NYSE: NVO ) decision to use "Novo" as its day-to-day name is part of a broader attempt by CEO Mike Doustdar to reset the company's culture and sharpen its competitive focus. The rebrand comes as Novo tries to regain momentum in obesity drugs after losing ground to Eli Lilly. Doustdar's new "Novo Way" emphasizes customer focus, competitiveness, clarity, and care, reflecting his view that the company needs to become more responsive to patients and consumers rather than relying primarily on its historical position in the market. Reuters similarly describes the move as a cultural reset aimed at reclaiming competitiveness.

The timing is important because Novo's challenge is no longer simply developing effective obesity medicines; it is competing more aggressively across distribution, pricing, patient access and product formats. Novo pioneered the modern obesity-drug market with Wegovy in the U.S. in 2021, but Eli Lilly has subsequently gained ground with Zepbound and more aggressive consumer-focused commercialization. Doustdar is therefore framing the change as an organizational transformation designed to make Novo "better and bigger," rather than merely changing its corporate identity.

Rethinking the Playbook Could Help Novo Close the Gap With Lilly

The strongest implication from the news is that Novo Nordisk A/S (NYSE:NVO) recognizes its competitive weaknesses while it still has substantial assets to build on. Wegovy remains a major franchise, and Novo has moved into oral obesity treatment with its Wegovy pill. That is strategically important because Novo expects oral drugs to account for more than one-third of GLP-1 obesity-treatment use by 2030. The company therefore has an opportunity to translate its existing obesity expertise into a new, potentially much larger patient population, particularly people reluctant to use injectable medicines.

The market itself also provides room for Novo Nordisk A/S (NYSE:NVO) to recover. Analysts expect the U.S. obesity-treatment market to exceed $100 billion annually by 2030. Novo's Wegovy pill had captured roughly 90% of the U.S. oral-obesity market as of August, although Lilly subsequently said its Foundayo treatment had already captured more than 30% of new U.S. oral-treatment patients. The message from Doustdar is therefore not that Novo has lost its competitive position, but that it needs to operate differently to defend and expand it.

The Bigger Challenge Lies Beyond Novo's New Name

The rebrand also underscores how much Novo Nordisk A/S (NYSE:NVO)'s competitive position has changed. The company was the first major player in the U.S. weight-loss-drug market, yet management is now explicitly talking about becoming more competitive and more customer-focused after Lilly gained ground. That suggests the problem extends beyond the effectiveness of Novo's medicines to how effectively it commercializes them and responds to changing consumer behavior.